Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has seen a significant decrease in its shares held by Bank of Nova Scotia. The bank sold 286,862 shares in the fourth quarter, reducing its position in the company by 97.8%. As a result, Bank of Nova Scotia now owns only 6,443 shares of Apellis Pharmaceuticals, worth approximately $386,000. Other hedge funds have also made changes to their holdings of APLS. Analysts have given various ratings to APLS, with an average rating of 'Moderate Buy' and a consensus target price of $74.38. Insiders have been actively selling company stock, with a total of 192,012 shares sold in the last 90 days, worth over $9.6 million. Apellis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic compounds for autoimmune and inflammatory diseases. The company offers EMPAVELI for the treatment of various conditions, including paroxysmal nocturnal hemoglobinuria and glomerulonephritis, as well as SYFOVRE for age-related macular degeneration. The stock has a market cap of $4.90 billion and a price-to-earnings ratio of -11.67. It reported earnings per share of ($0.54) for the last quarter, in line with analysts' expectations. The company's revenue for the quarter was $172.33 million, representing a significant year-over-year increase of 284.3%. For the current fiscal year, Apellis Pharmaceuticals is expected to post earnings per share of -1.15. It is important to note that investing in biopharmaceutical companies carries inherent risks and investors should conduct thorough research before making any investment decisions. [c4fbb4b0]
Novo Nordisk A/S has initiated a share repurchase programme in accordance with regulations. The programme, which began on May 6, 2024, is part of an overall share repurchase programme of up to DKK 20 billion to be executed over a 12-month period starting on February 6, 2024. Under the current programme, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. As of June 28, 2024, Novo Nordisk has repurchased a total of 10,061,625 B shares at an average share price of DKK 873.45 per B share, equal to a transaction value of DKK 8,788,370,170. Novo Nordisk currently owns a total of 11,427,189 B shares as treasury shares, corresponding to 0.3% of the share capital. The company expects to repurchase B shares for an amount up to DKK 20 billion during the 12-month period. Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. It employs about 66,000 people in 80 countries and markets its products in around 170 countries. [bc7d7c46]